Cardiac Dimensions, a Kirkland, Wash., company with a technology to treat heart valve malfunction, has raised $53 million from investors. Its total funding is more than $200 million.
Cardiac Dimensions is targeting a condition called mitral valve regurgitation, which involves the leakage of blood through the heart’s mitral valve during the contraction of the left ventricle. The condition can lead to an enlarged heart and is associated with congestive heart failure.
The company’s Carillon Mitral Contour System is designed to tighten the leaky valve through a minimally invasive procedure.
The new funding positions the company “to continue our global commercial expansion of the Carillon therapy to improve the lives of patients with this debilitating disease,” said CEO and president Rick Wypych in a statement.